MediWound Q3 revenue falls to $3.6M as EscharEx VALUE trial nears full enrolment
The Israeli wound-care company reports a $6.0M quarterly net loss, a clean DSMB review and successful GMP inspections, while 2026 revenue hinges on uncertain US government funding.
MediWound reported third-quarter 2026 revenue of $3.6M on 12 November, down from $5.4M a year earlier. The company posted a net loss of $6.0M for the period.
The Phase III VALUE trial of EscharEx in venous leg ulcers remains on track, according to the company. It expects to carry out an interim reassessment and complete full enrolment by the end of the first quarter of 2027. The independent data safety monitoring board (DSMB) reviewed the study and raised no safety concerns.
On the manufacturing side, the facility that produces NexoBrid has passed GMP inspections by the US FDA and by the Israeli Ministry of Health, the latter acting on behalf of the European Medicines Agency (EMA). GMP inspections check that a site manufactures medicines under controlled, documented quality systems.
MediWound also closed a $17.25M public offering in November. The company cautioned that its 2026 revenue depends on the outcome of uncertain talks over US government funding.
Why it matters
- Quality teams: a successful FDA inspection and an Israeli MoH inspection on behalf of the EMA give the NexoBrid site a clean GMP record across both regions.
- Clinical and PV teams: the DSMB's lack of safety concerns is a positive signal for VALUE, though the interim reassessment and enrolment completion are still pending in Q1 2027.
- Market-access teams: revenue dependence on US government funding talks points to continued uncertainty in NexoBrid supply and revenue planning.
Company's press release (SEC filing): MediWound Ltd. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
